MOTS-c vs SS-31

• MOTS-c is a mitochondrial-derived peptide encoded by mitochondrial DNA; SS-31 (Elamipretide) is a synthetic peptide that targets cardiolipin in the inner mitochondrial membrane.
• MOTS-c research focuses on metabolic regulation and exercise mimetic effects; SS-31 research emphasizes mitochondrial dysfunction and cardioprotection.
• SS-31 has advanced further in clinical trials, including Phase 2/3 studies for Barth syndrome and heart failure.
• MOTS-c activates AMPK and influences glucose metabolism; SS-31 stabilizes the electron transport chain by binding cardiolipin.
• Both represent a growing field of mitochondria-targeted peptide therapeutics.

MOTS-c and SS-31 both target mitochondrial function but through entirely different mechanisms — MOTS-c as an endogenous signaling peptide and SS-31 as a synthetic membrane-targeting compound.

Side-by-Side Comparison

When Researchers Compare Them

MOTS-c and SS-31 represent two distinct approaches to mitochondrial therapeutics. MOTS-c is an endogenous mitochondrial-derived peptide (MDP), meaning it is naturally encoded within mitochondrial DNA. Research has shown it activates AMPK, enhances glucose uptake, and may function as an exercise mimetic — making it a subject of interest in metabolic disease and aging research.

SS-31 (also known as Elamipretide or Bendavia) is a synthetic tetrapeptide designed to penetrate cell membranes and selectively bind cardiolipin, a phospholipid critical to the inner mitochondrial membrane. By stabilizing the electron transport chain, SS-31 aims to restore mitochondrial efficiency in conditions where mitochondrial dysfunction is a driver of disease.

SS-31 has progressed further in the clinical pipeline, with Phase 2 and 3 trials conducted in Barth syndrome, age-related macular degeneration, and heart failure with preserved ejection fraction. MOTS-c research remains primarily preclinical but is rapidly expanding.

Peptide Profiles

Citations

1. [1] Lee C. et al. — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab. 2015 Source
2. [2] Lee C. et al. — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab. 2015 Source
3. [3] MOTS-c prevents pancreatic islet cell senescence to delay diabetes — Exp Mol Med. 2025 Source
4. [4] MOTS-c restores mitochondrial respiration in type 2 diabetic heart — Frontiers Physiol. 2025 Source
5. [5] MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline — Nature Commun. 2021 Source
6. [6] MOTS-c in type 2 diabetes mellitus: From risk factors to cardiac complications — Life Sciences 2026 Source
7. [7] FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee Source
8. [8] STAT — An obesity drug deep-dive, and peptides move mainstream (June 11, 2026) Source
9. [9] FDA Approves FORZINITY (elamipretide) for Barth Syndrome — Stealth BioTherapeutics, September 2025 Source
10. [10] UMDF — FDA Approves First Mitochondrial Disease Therapy Source
11. [11] Johns Hopkins Hub — FDA approves drug for Barth syndrome, September 2025 Source
12. [12] Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential — IJMS. 2026 Source
13. [13] SS-31 treatment ameliorates cardiac mitochondrial morphology in Barth syndrome model — Scientific Reports. 2024 Source

Related Peptides